Althea Group Holdings Ltd (ASX: AGH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Althea Group Holdings Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$12.16 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
405.33 million
Earnings per share
-0.058
Dividend per share
N/A
Year To Date Return
-23.08%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Althea Group Holdings Ltd (ASX: AGH)
Latest News
Coronavirus News
Here's how ASX cannabis shares are being impacted by COVID-19
Share Market News
How did ASX cannabis shares perform this reporting season?
Share Market News
Why this ASX cannabis share is sinking lower today
Share Market News
How have these 3 ASX cannabis shares kicked off 2020?
Share Gainers
Why Althea, Appen, Challenger, & De Grey Mining are surging higher
Share Gainers
Why this ASX cannabis share is smoking the market today
Share Gainers
Why this ASX cannabis share jumped 12% higher today
Share Market News
Why these 2 ASX cannabis shares are flying higher this week
Share Market News
ALL ORDINARIES finishes higher Tuesday: 8 ASX shares you missed
Share Gainers
Why this ASX cannabis stock is soaring today
Share Market News
What's in store for these 4 ASX cannabis shares in 2020?
Share Gainers
Why Cann and these ASX shares are rocketing higher today
AGH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Althea Group Holdings Ltd
Althea Group Holdings Ltd is engaged in the manufacturing, sales, and distribution of cannabis-based medicines and recreational cannabis products. It operates in three reportable segments Pharmaceutical Cannabis, Recreational Cannabis, andCorporate in which it generates the majority of its revenue from Pharmaceutical Cannabis. It operates into four geographic segments: Australia, the United Kingdom, Canada, and others. The company earns key revenue from Australia and through the sale of medicinal cannabis products.
AGH Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 22 Apr 2024 | $0.03 | $0.00 | 0.00% | 337,875 | $0.03 | $0.03 | $0.03 |
| 19 Apr 2024 | $0.03 | $0.00 | 0.00% | 42,590 | $0.03 | $0.03 | $0.03 |
| 18 Apr 2024 | $0.03 | $0.00 | 0.00% | 29,681 | $0.03 | $0.03 | $0.03 |
| 17 Apr 2024 | $0.03 | $0.00 | 0.00% | 11,764 | $0.03 | $0.03 | $0.03 |
| 16 Apr 2024 | $0.03 | $0.00 | 0.00% | 87,573 | $0.03 | $0.03 | $0.03 |
| 15 Apr 2024 | $0.03 | $0.00 | 0.00% | 206,911 | $0.03 | $0.03 | $0.03 |
| 12 Apr 2024 | $0.03 | $0.00 | 0.00% | 701,592 | $0.03 | $0.03 | $0.03 |
| 11 Apr 2024 | $0.03 | $0.00 | 0.00% | 29,444 | $0.03 | $0.03 | $0.03 |
| 10 Apr 2024 | $0.03 | $0.00 | 0.00% | 54,622 | $0.03 | $0.03 | $0.03 |
| 09 Apr 2024 | $0.03 | $0.00 | 0.00% | 152,726 | $0.03 | $0.03 | $0.03 |
| 08 Apr 2024 | $0.03 | $0.00 | 0.00% | 278,269 | $0.03 | $0.03 | $0.03 |
| 05 Apr 2024 | $0.03 | $0.00 | 0.00% | 223,142 | $0.03 | $0.03 | $0.03 |
| 04 Apr 2024 | $0.03 | $0.00 | 0.00% | 284,286 | $0.03 | $0.03 | $0.03 |
| 03 Apr 2024 | $0.03 | $0.00 | 0.00% | 240,556 | $0.03 | $0.03 | $0.03 |
| 02 Apr 2024 | $0.03 | $0.00 | 0.00% | 1,175,852 | $0.03 | $0.03 | $0.03 |
| 28 Mar 2024 | $0.03 | $0.00 | 0.00% | 31,403 | $0.03 | $0.03 | $0.03 |
| 27 Mar 2024 | $0.03 | $0.00 | 0.00% | 354,851 | $0.03 | $0.03 | $0.03 |
| 26 Mar 2024 | $0.03 | $0.00 | 0.00% | 602,166 | $0.03 | $0.03 | $0.03 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 01 Sep 2023 | Alan Boyd | Issued | 149,254 | $10,000 |
As advised by the company. Participation in a capital raise
|
| 01 Sep 2023 | Philip Newbold | Issued | 746,269 | $50,000 |
As advised by the company. Participation in a capital raise
|
| 01 Sep 2023 | Joshua Fegan | Issued | 1,194,030 | $80,000 |
As advised by the company. Participation in Capital Raise, As per announcement on 01-09-2023
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Alan Maclean Boyd | Non-Executive Director | Jun 2018 |
Mr Boyd was the Chief Financial Officer of Ridley Corporation Limited, an ASX-listed provider of high-performance animal nutrition solutions. Prior to his role, Alan occupied the same position with listed biotechnology companies Avexa Limited and Zenyth Therapeutics Limited, website pioneer Sausage Software Limited, and un-listed public entity HRL Limited, where he later served as a non-executive director and Chair of the Audit Committee. Alan started his professional career in chartered accounting firms in England and Australia and has broad financial experience across many industry sectors.
He is Chair of Risk and Compliance Management Committee. |
| Mr Philip Andrew Newbold | Non-Executive ChairmanNon-Executive Director | Jun 2018 |
Mr Newbold has practised for nearly 20 years at a large commercial firm. He founded a renewable energy business which he sold to Origin Energy. Since that time, he has been involved in a start-up property app business which he sold to ANZ in 2015 and various other businesses. Andrew has been a director of numerous private companies and not-for-profit organisations and currently is a director of Supra Capital, a Commissioner of the AFL and Chairman of Golf Australia.
He is member of Risk and Compliance Management Committee. |
| Mr Joshua Michael Fegan | Chief Executive OfficerManaging Director | Jun 2018 |
Mr Fegan is the founder of Althea Group Holdings Limited and has extensive experience in business building, sales and marketing. He has a range of proven business and strategy skills and has previously held a number of senior management roles at national value-based retailer, Strathfield Group. Joshua founded Althea Health and Wellbeing.
|
| Penelope Dobson | Non-Executive Director | Nov 2018 |
Ms Dobson is an experienced global healthcare executive. She has worked in the broad life-science space since her training as a pharmacist in New Zealand, including many years in the global pharmaceutical industry. Penny is currently a Principal at Valida Consulting, offering a range of services to companies in the healthcare, Pharma,
Biotech, not-for-profit, Device and Diagnostics sector. She is member of Risk and Compliance Management Committee. |
| Mr Robert Meissner | Chief Financial OfficerCompany Secretary | Apr 2019 |
-
|
| Robert Meissner | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Joshua Michael Fegan | 56,250,000 | 14.34% |
| Hsbc Custody Nominees (Australia) Limited | 26,002,357 | 6.63% |
| Citicorp Nominees Pty Limited | 11,055,551 | 2.82% |
| Obsidian Global Gp Llc | 10,360,036 | 2.64% |
| Mancann Pty Ltd | 10,000,000 | 2.55% |
| Hootch Pty Ltd | 7,500,000 | 1.91% |
| Hosanda Corporation Pty Limited | 4,250,000 | 1.08% |
| Bnp Paribas Nominees Pty Ltd <Ib. Au Noms Retail Client Drp> | 4,249,269 | 1.08% |
| Mr Ingo Appel | 4,000,000 | 1.02% |
| Mid Dig Investments Pty Ltd <Mid Dig Super Fund A/C> | 3,761,813 | 0.96% |
| Mr Philip John Cawood | 2,770,834 | 0.71% |
| Pither Investments Pty Ltd <Pither Investments A/C> | 2,550,000 | 0.65% |
| Tilkeridis Investments Pty Ltd <Tilkeridis Family A/C> | 2,400,763 | 0.61% |
| Pac Partners Securities Pty Ltd | 2,397,545 | 0.61% |
| J P Morgan Nominees Australia Pty Limited | 2,385,664 | 0.61% |
| Nurturing Evolutionary Development Pty Ltd | 2,180,000 | 0.56% |
| Adman Lanes Pty Ltd | 2,150,000 | 0.55% |
| Mr Hooi Giap Toh <Yang And Toh Family A/C> | 2,000,000 | 0.51% |
| Palmos Investments Pty Limited <Palmos Property A/C> | 2,000,000 | 0.51% |
| Mr Robin Poulose Thekkekara | 1,891,745 | 0.48% |
